Zura Bio (Zura Bio) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Zura Bio's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Zura Bio's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.38.

Zura Bio Accounts Receivable Historical Data

The historical data trend for Zura Bio's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Accounts Receivable Chart

Zura Bio Annual Data

Trend

Dec21

Mar22

Dec23

Accounts Receivable

Zura Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial					-	-	-	-	-

Zura Bio Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Zura Bio Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Zura Bio's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Zura Bio's accounts receivable are only considered to be worth 75% of book value:

Zura Bio's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(89.817	+	0.75 * 0	+	0.5 * 0	-	16.27
-	0	-	13.204)	/	43.5937
=	1.38

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Zura Bio Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Zura Bio's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Zura Bio (Zura Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

94E:Germany

Address

4225 Executive Square, Suite 600, La Jolla, CA, USA, 92037

Website

https://www.zurabio.com

Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.

Executives

Parvinder Thiara	director, 10 percent owner	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Amit Munshi	director	C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni	director	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kimberly Ann Davis	officer: Secretary and General Counsel	C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Gary Whale	officer: EVP and CTO	2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Theresa Lowry	officer: EVP and CHRO	3629 VILLA TERRACE, SAN DIEGO CA 92104
Michael Howell	officer: SVP, Translational Medicine	4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Hana Immunotherapeutics Llc	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Chris Kim	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Ewon Comfortech Co., Ltd.	10 percent owner	8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Steven J Schoch	director	2748 BUSH STREET, SAN FRANCISCO CA 94115
Preston Klassen	officer: President and COO	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Cabell	officer: EVP and CMO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jennifer Jarrett	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105